Which has stronger valuation & earnings, INSM or ARGX?

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 36.45 -$1.28B -$5.75 N/A argenex $4.66B 11.34 $1.29B $22.46 37.83

Is INSM or ARGX more profitable?

argenex has a net margin of 31.31% compared to Insmed's net margin of -144.44%. argenex's return on equity of 44.37% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% argenex 31.31% 44.37% 37.55%

Does the media prefer INSM or ARGX?

In the previous week, Insmed had 11 more articles in the media than argenex. MarketBeat recorded 13 mentions for Insmed and 2 mentions for argenex. Insmed's average media sentiment score of 1.32 beat argenex's score of 0.00 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INSM or TAK?

Insmed currently has a consensus target price of $211.86, indicating a potential upside of 107.77%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 1 Sell rating(s) 0 Hold rating(s) 23 Buy rating(s) 1 Strong Buy rating(s) 2.96 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to INSM or TAK?

In the previous week, Insmed had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for Insmed and 1 mentions for Takeda Pharmaceutical. Insmed's average media sentiment score of 1.32 beat Takeda Pharmaceutical's score of 0.57 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TEVA or INSM?

In the previous week, Teva Pharmaceutical Industries had 18 more articles in the media than Insmed. MarketBeat recorded 31 mentions for Teva Pharmaceutical Industries and 13 mentions for Insmed. Insmed's average media sentiment score of 1.32 beat Teva Pharmaceutical Industries' score of 0.96 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 19 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVMD or INSM?

In the previous week, Revolution Medicines had 9 more articles in the media than Insmed. MarketBeat recorded 22 mentions for Revolution Medicines and 13 mentions for Insmed. Insmed's average media sentiment score of 1.32 beat Revolution Medicines' score of 0.29 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, INSM or ONC?

BeOne Medicines has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 36.45 -$1.28B -$5.75 N/A BeOne Medicines $5.34B 5.65 $286.93M $4.47 61.54

Is INSM or ONC more profitable?

BeOne Medicines has a net margin of 8.94% compared to Insmed's net margin of -144.44%. BeOne Medicines' return on equity of 12.06% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% BeOne Medicines 8.94% 12.06% 6.69%

Does the media favor INSM or ONC?

In the previous week, Insmed had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 13 mentions for Insmed and 11 mentions for BeOne Medicines. Insmed's average media sentiment score of 1.32 beat BeOne Medicines' score of -0.18 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Insmed (INSM) Competitors

$101.97 +3.36 (+3.41%)

As of 03:52 PM Eastern

Compare

INSM vs. ARGX, TAK, TEVA, RVMD, and ONC

Should you buy Insmed stock or one of its competitors? MarketBeat compares Insmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insmed include argenex (ARGX), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does Insmed compare to argenex?

Insmed (NASDAQ:INSM) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

In the previous week, Insmed had 11 more articles in the media than argenex. MarketBeat recorded 13 mentions for Insmed and 2 mentions for argenex. Insmed's average media sentiment score of 1.32 beat argenex's score of 0.00 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.45	-$1.28B	-$5.75	N/A
argenex	$4.66B	11.34	$1.29B	$22.46	37.83

Insmed presently has a consensus target price of $211.86, suggesting a potential upside of 107.77%. argenex has a consensus target price of $1,019.50, suggesting a potential upside of 19.98%. Given Insmed's stronger consensus rating and higher possible upside, research analysts plainly believe Insmed is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

argenex has a net margin of 31.31% compared to Insmed's net margin of -144.44%. argenex's return on equity of 44.37% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
argenex	31.31%	44.37%	37.55%

60.3% of argenex shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Summary

argenex beats Insmed on 10 of the 17 factors compared between the two stocks.

How does Insmed compare to Takeda Pharmaceutical?

Insmed (NASDAQ:INSM) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 4.31% compared to Insmed's net margin of -144.44%. Takeda Pharmaceutical's return on equity of 11.20% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.45	-$1.28B	-$5.75	N/A
Takeda Pharmaceutical	$4.51T	0.01	-$1.01B	$0.39	40.54

In the previous week, Insmed had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for Insmed and 1 mentions for Takeda Pharmaceutical. Insmed's average media sentiment score of 1.32 beat Takeda Pharmaceutical's score of 0.57 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Insmed currently has a consensus target price of $211.86, indicating a potential upside of 107.77%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Insmed beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Insmed compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Teva Pharmaceutical Industries currently has a consensus target price of $41.78, indicating a potential upside of 25.50%. Insmed has a consensus target price of $211.86, indicating a potential upside of 107.77%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Teva Pharmaceutical Industries had 18 more articles in the media than Insmed. MarketBeat recorded 31 mentions for Teva Pharmaceutical Industries and 13 mentions for Insmed. Insmed's average media sentiment score of 1.32 beat Teva Pharmaceutical Industries' score of 0.96 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	19 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Insmed's net margin of -144.44%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Insmed	-144.44%	-130.11%	-51.57%

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.35B	2.21	$1.41B	$1.33	25.03
Insmed	$606.42M	36.45	-$1.28B	-$5.75	N/A

Summary

Teva Pharmaceutical Industries beats Insmed on 10 of the 17 factors compared between the two stocks.

How does Insmed compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

In the previous week, Revolution Medicines had 9 more articles in the media than Insmed. MarketBeat recorded 22 mentions for Revolution Medicines and 13 mentions for Insmed. Insmed's average media sentiment score of 1.32 beat Revolution Medicines' score of 0.29 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Revolution Medicines has higher earnings, but lower revenue than Insmed. Revolution Medicines is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
Insmed	$606.42M	36.45	-$1.28B	-$5.75	N/A

94.3% of Revolution Medicines shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Revolution Medicines currently has a consensus price target of $123.72, indicating a potential downside of 26.30%. Insmed has a consensus price target of $211.86, indicating a potential upside of 107.77%. Given Insmed's higher possible upside, analysts clearly believe Insmed is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Revolution Medicines has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Revolution Medicines' return on equity of -83.22% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Insmed	-144.44%	-130.11%	-51.57%

Summary

Revolution Medicines beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Insmed compare to BeOne Medicines?

Insmed (NASDAQ:INSM) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

BeOne Medicines has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.45	-$1.28B	-$5.75	N/A
BeOne Medicines	$5.34B	5.65	$286.93M	$4.47	61.54

Insmed presently has a consensus price target of $211.86, suggesting a potential upside of 107.77%. BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 41.77%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts clearly believe Insmed is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

BeOne Medicines has a net margin of 8.94% compared to Insmed's net margin of -144.44%. BeOne Medicines' return on equity of 12.06% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
BeOne Medicines	8.94%	12.06%	6.69%

48.6% of BeOne Medicines shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Insmed had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 13 mentions for Insmed and 11 mentions for BeOne Medicines. Insmed's average media sentiment score of 1.32 beat BeOne Medicines' score of -0.18 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Summary

BeOne Medicines beats Insmed on 10 of the 17 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INSM vs. The Competition

Export

Metric	Insmed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.10B	$3.46B	$6.47B	$12.14B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-17.73	20.12	24.67	24.05
Price / Sales	36.45	293.90	518.45	102.06
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	29.47	8.31	10.83	6.55
Net Income	-$1.28B	$23.85M	$3.56B	$336.99M
7 Day Performance	6.75%	5.33%	1.75%	-0.10%
1 Month Performance	-4.02%	2.32%	0.51%	0.90%
1 Year Performance	-3.27%	61.13%	32.92%	31.76%

Insmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INSM Insmed	3.4857 of 5 stars	$101.97 +3.4%	$211.86 +107.8%	-4.0%	$22.10B	$606.42M	N/A	1,664	Positive News
ARGX argenex	3.0822 of 5 stars	$884.20 -1.0%	$1,019.50 +15.3%	+66.7%	$55.57B	$4.25B	39.37	1,863
TAK Takeda Pharmaceutical	2.2969 of 5 stars	$15.76 -1.0%	N/A	+4.8%	$50.63B	$28.32B	40.40	47,455	Analyst Downgrade
TEVA Teva Pharmaceutical Industries	4.5791 of 5 stars	$33.66 -2.8%	$41.78 +24.1%	+90.0%	$39.82B	$17.26B	25.30	33,950	Positive News Options Volume
RVMD Revolution Medicines	1.6592 of 5 stars	$160.06 +4.0%	$123.72 -22.7%	+318.1%	$32.71B	$11.58M	N/A	250	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INSM) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insmed (INSM) Competitors

INSM vs. ARGX, TAK, TEVA, RVMD, and ONC

How does Insmed compare to argenex?

Summary

How does Insmed compare to Takeda Pharmaceutical?

Summary

How does Insmed compare to Teva Pharmaceutical Industries?

Summary

How does Insmed compare to Revolution Medicines?

Summary

How does Insmed compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insmed (INSM) Competitors

INSM vs. ARGX, TAK, TEVA, RVMD, and ONC

How does Insmed compare to argenex?

Does the media prefer INSM or ARGX?

Which has stronger valuation & earnings, INSM or ARGX?

Do analysts prefer INSM or ARGX?

Is INSM or ARGX more profitable?

Do insiders & institutionals hold more shares of INSM or ARGX?

Which has more risk and volatility, INSM or ARGX?

Summary

How does Insmed compare to Takeda Pharmaceutical?

Do institutionals and insiders believe in INSM or TAK?

Is INSM or TAK more profitable?

Which has stronger earnings and valuation, INSM or TAK?

Does the media refer more to INSM or TAK?

Which has more risk & volatility, INSM or TAK?

Do analysts recommend INSM or TAK?

Summary

How does Insmed compare to Teva Pharmaceutical Industries?

Do analysts rate TEVA or INSM?

Does the media refer more to TEVA or INSM?

Which has more risk & volatility, TEVA or INSM?

Is TEVA or INSM more profitable?

Do institutionals & insiders have more ownership in TEVA or INSM?

Which has better earnings & valuation, TEVA or INSM?

Summary

How does Insmed compare to Revolution Medicines?

Does the media favor RVMD or INSM?

Which has more risk and volatility, RVMD or INSM?

Which has stronger earnings & valuation, RVMD or INSM?

Do institutionals and insiders believe in RVMD or INSM?

Do analysts rate RVMD or INSM?

Is RVMD or INSM more profitable?

Summary

How does Insmed compare to BeOne Medicines?

Which has stronger earnings & valuation, INSM or ONC?

Do analysts rate INSM or ONC?

Is INSM or ONC more profitable?

Do institutionals and insiders hold more shares of INSM or ONC?

Does the media favor INSM or ONC?

Which has more volatility and risk, INSM or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools